

Boris Sepesi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7871367/boris-sepesi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

3,945
citations

30
h-index

58
g-index

181
ext. papers

5,753
ext. citations

5
avg, IF

5.23
L-index

#	Paper	IF	Citations
160	Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022 ,	1.5	3
159	Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101589	2.2	12
158	Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100288	1.4	
157	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.. <i>Lung Cancer</i> , 2022 , 164, 69-75	5.9	0
156	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era.. <i>Journal of Surgical Research</i> , 2022 , 277, 125-130	2.5	
155	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 1404-1412.e25	1.5	8
154	Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. <i>Surgery</i> , 2021 ,	3.6	1
153	Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. <i>Annals of Surgery</i> , 2021 , 274, 1099-1106	7.8	10
152	Simultaneous versus staged resections for bilateral pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2021 , 123, 1633-1639	2.8	2
151	Single-Cell Expression Landscape of SARS-CoV-2 Receptor and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
150	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021 , 154, 76-83	5.9	5
149	Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	1
148	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 583-600	8.9	18
147	Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?. <i>Lancet Oncology</i> , 2021 , 22, 744-746	21.7	1
146	Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. <i>Journal of Surgical Oncology</i> , 2021 , 124, 699-703	2.8	2
145	Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8542-8542	2.2	0
144	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021 , 11, 2506-2523	24.4	15

143	Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8557-8557	2.2	
142	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021 , 12, 2722	17.4	16
141	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	2
140	Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	0
139	Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, 1497-1504.e2	1.5	14
138	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021 , 22, e415-e424	4.9	5
137	Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 296-305	1.5	13
136	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1133-1140	2.7	2
135	Predictors of survival following surgical resection of limited-stage small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, 760-771.e2	1.5	12
134	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 127-139	8.9	14
133	Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1111-1117	2.7	
132	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2021 , 59, 100-108	3	5
131	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 590-606	4.4	11
130	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. <i>Nature Communications</i> , 2021 , 12, 687	17.4	9
129	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. <i>Scientific Reports</i> , 2021 , 11, 4530	4.9	12
128	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021 , 27, 504-514	50.5	105
127	Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 2185-2191	3.3	0
126	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 5045	17.4	6

125	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1289-1297	8.9	6
124	Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. <i>Annals of Thoracic Surgery</i> , 2021 , 112, 423-429	2.7	3
123	Optimizing Discharge After Shorter Hospitalizations: Lessons Learned Through After-Hours Calls with Thoracic Surgical Patients. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021 , 16, 529-535	1.5	1
122	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. <i>Lancet Oncology</i> , 2021 , 22, 1448-1457	21.7	26
121	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1965-1976	7.4	1
120	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	2
119	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021 , 12, 7081	17.4	1
118	Barriers to surveillance imaging adherence in early-staged lung cancer.. <i>Journal of Thoracic Disease</i> , 2021 , 13, 6848-6854	2.6	0
117	Single Chest Drain Practice Reduces Discharge Opioid Prescriptions in Thoracic Surgery. <i>Thoracic and Cardiovascular Surgeon</i> , 2021 ,	1.6	1
116	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort 2020 , 8,		13
115	Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. <i>Journal of Surgical Oncology</i> , 2020 , 122, 515-522	2.8	0
114	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020 , 10, 626	5.3	5
113	Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. <i>Human Pathology</i> , 2020 , 98, 98-109	3.7	5
112	Commentary: Salvage Resection for Stage IIIA Lung Cancer in the Era of Immunotherapy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020 , 32, 160-161	1.7	1
111	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020 , 146, 303-309	5.9	2
110	Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. <i>Journal of Thoracic Disease</i> , 2020 , 12, 184-190	2.6	2
109	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. <i>Journal of Thoracic Disease</i> , 2020 , 12, 1952-1959	2.6	4
108	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2020 , 121, 984-989	2.8	

107	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020 , 21, e294-e301	4.9	4
106	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3525-3536	12.9	9
105	Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. <i>Journal of Surgical Oncology</i> , 2020 , 122, 495-505	2.8	5
104	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020 , 21, 341-348	4.9	27
103	BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9624-9624	2.2	2
102	Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e75-e77	8.9	0
101	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 1131-1138	2.7	4
100	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1449-1459	8.9	49
99	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020 , 11, 603	17.4	67
98	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020 , 32, 337-343	1.7	4
97	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020 , 26, 39-46	50.5	119
96	Perioperative outcomes among chronic opioid users who receive lobectomy for non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 691-702.e5	1.5	2
95	Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2020 , 15, 57-65	1.5	3
94	Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020 , 29, 555-569	2.7	3
93	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020 , 26, 5477-5486	12.9	12
92	Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 404-411	2.7	6
91	Persistent Opioid Use Among the Elderly After Lung Resection: A SEER-Medicare Study. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 194-202	2.7	7
90	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 358-366	2.7	2

89	Commentary: Neoadjuvant checkpoint inhibitors in resectable non-small cell lung cancer-Ready for prime time?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 1624-1625	1.5	2
88	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 37-46.e7	4.9	26
87	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1519-1534	7.4	11
86	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. <i>Journal of Thoracic Disease</i> , 2020 , 12, 329-337	2.6	1
85	Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 924-929	1.5	6
84	Local failure after stereotactic body radiation therapy or wedge resection for colorectal pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 1234-1241.e16	1.5	8
83	Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 936-940	2.7	10
82	A case report of a midesophageal diverticulum mimicking a fibrovascular esophageal polyp. <i>International Journal of Surgery Case Reports</i> , 2019 , 59, 205-207	0.8	1
81	Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. <i>Journal of Thoracic Disease</i> , 2019 , 11, 1269-1278	2.6	11
80	Local Recurrence After Microwave Ablation of Lung Malignancies: A Systematic Review. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 1876-1883	2.7	14
79	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1558-1565	2.2	445
78	Centrally located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	17
77	Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 845-851	2.7	5
76	Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 370-376	2.7	25
75	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 911-919.e6	1.5	11
74	Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 279-286.e1 ²²	1.5	22
73	Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. <i>Cancer</i> , 2019 , 125, 3738-3748	6.4	13
72	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. <i>Journal of Surgical Oncology</i> , 2019 , 120, 729-735	2.8	9

71	Mediastinal esophageal leiomyosarcoma abutting a retroesophageal right subclavian artery: A case report. <i>International Journal of Surgery Case Reports</i> , 2019 , 60, 281-283	0.8	
70	A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1343-1353	8.9	27
69	Lung Cancer Patient Perceptions of the Value of an Outreach Thoracic Surgical Clinic. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 358-362	2.7	1
68	Commentary: Surgery for N3 non-small cell lung cancer-utopia or future reality?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 1693-1694	1.5	1
67	Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. <i>Journal of Thoracic Disease</i> , 2019 , 11, 3391-3398	2.6	3
66	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8504-8504	2.2	80
65	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9017-9017	2.2	7
64	Glutathione reductase () gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. <i>American Journal of Cancer Research</i> , 2019 , 9, 1201-1211	4.4	1
63	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14047-e14047	2.2	0
62	Persistent opioid use is associated with worse survival after lobectomy for stage I non-small cell lung cancer. <i>Pain</i> , 2019 , 160, 2365-2373	8	21
61	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 157, 1648-1655	1.5	13
60	Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 277-284	2.7	11
59	Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 960-966	3	13
58	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 155, 2635-2645.e15	1.5	2
57	Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1671-1677	2.7	11
56	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018 , 8, 1922	4.9	70
55	TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic -Mutant Mouse Lung Cancer Models. <i>Cancer Immunology Research</i> , 2018 , 6, 163-177	12.5	12
54	Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 1090-1097	4.097	36

53	Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018 , 4, e174504	13.4	25
52	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1621-1626	2.7	4
51	Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 235-241	2.7	8
50	Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 272-279	2.7	98
49	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 779-791	8.9	39
48	Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 156, 406-413.e3	1.5	9
47	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches 2018 , 6, 48		76
46	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) 2018 , 6, 75		107
45	Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. <i>Journal of Surgical Oncology</i> , 2018 , 118, 518-524	2.8	9
44	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. <i>Cancer</i> , 2018 , 124, 1061-1069	6.4	8
43	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 418-424	2.7	14
42	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1155-1167	8.9	50
41	Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 1499-1503	2.7	4
40	Management of Breast Cancer Invading Chest Wall. <i>Thoracic Surgery Clinics</i> , 2017 , 27, 159-163	3.1	6
39	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017 , 5, 319-329	12.5	9
38	Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 983-992	8.9	41
37	Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1419-1427	3.1	3
36	Cancer of the Lung 2017 , 1-30		0

35	Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017 , 154, 689-699	1.5	37
34	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. <i>Annals of Thoracic Surgery</i> , 2017 , 103, 1710-1714	2.7	7
33	The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1280-1287	8.9	38
32	OA20.06 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer - The ICON Project. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S324-S325	8.9	3
31	Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 619-626	5.1	19
30	Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 1821-1828	2.7	5
29	Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3354-3362	2.2	58
28	Systolic anterior motion of the mitral valve-the mechanism of postural hypotension following left intrapericardial pneumonectomy. <i>Journal of Thoracic Disease</i> , 2017 , 9, E354-E357	2.6	0
27	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. <i>Cancer</i> , 2017 , 123, 4106-4113	6.4	61
26	Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues". <i>Journal of Thoracic Oncology</i> , 2017 , 12, e150-e151	8.9	1
25	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017 , 7, 1088-1097	24.4	105
24	Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature. <i>Frontiers in Oncology</i> , 2017 , 7, 228	5.3	8
23	Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017 , 29, 408-415	1.7	18
22	Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 211-7	2.7	8
21	The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 1653-1659	2.7	22
20	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 1672-1682	21.7	548
19	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 6278-6289	12.9	96
18	Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 276-81	2.7	16

17	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 1075-80; Discussion 1080-1	2.7	14
16	SABR vs surgery for NSCLC in the media. <i>Lancet Oncology, The</i> , 2015 , 16, e422	21.7	6
15	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. <i>Cancer Letters</i> , 2015 , 357, 179-185	9.9	68
14	Surgical therapy of ground-glass opacities. <i>Seminars in Diagnostic Pathology</i> , 2014 , 31, 289-92	4.3	7
13	The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. <i>Annals of Surgery</i> , 2013 , 258, 500-7	7.8	28
12	The influence of staple size on fistula formation following distal pancreatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2012 , 16, 267-74	3.3	40
11	Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 144, 1146-50	1.5	40
10	Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. <i>Cancer</i> , 2011 , 117, 63-9	6.4	36
9	A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. <i>Annals of Surgery</i> , 2010 , 252, 611-7	7.8	24
8	Esophageal perforation: surgical, endoscopic and medical management strategies. <i>Current Opinion in Gastroenterology</i> , 2010 , 26, 379-83	3	61
7	A population-based analysis of emergent vs. elective hospital admissions for an intrathoracic stomach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010 , 24, 1250-5	5.2	40
6	Should elective repair of intrathoracic stomach be encouraged?. <i>Journal of Gastrointestinal Surgery</i> , 2010 , 14, 203-10	3.3	41
5	Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. <i>Journal of the American College of Surgeons</i> , 2010 , 210, 418-27	4.4	141
4	Surgical resection for locoregional esophageal cancer is underutilized in the United States. <i>Journal of the American College of Surgeons</i> , 2010 , 211, 754-61	4.4	30
3	Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. <i>Journal of Gastrointestinal Surgery</i> , 2009 , 13, 2121-7	3.3	17
2	Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines. <i>Journal of Neuroscience</i> , 2002 , 22, 6114-20	6.6	105
1	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features		2